Development of177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators-Reference-Cited by-同舟云学术

Development of177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators

Published:2012-03 Issue:2 Volume:7 Page:254-264
ISSN:1555-4309
Container-title:Contrast Media & Molecular Imaging
language:en
Short-container-title:Contrast Media Mol. Imaging

Author:

D'Huyvetter Matthias¹²,Aerts An¹,Xavier Catarina²,Vaneycken Ilse²,Devoogdt Nick²,Gijs Marlies¹,Impens Nathalie¹,Baatout Sarah¹,Ponsard Bernard³,Muyldermans Serge⁴⁵,Caveliers Vicky²⁶,Lahoutte Tony²⁶

Affiliation:

1. Radiobiology Unit, Molecular and Cellular Biology Expert Group; Belgian Nuclear Research Center (SCK•CEN); Mol Belgium

2. In vivo Cellular and Molecular Imaging Laboratory; Vrije Universiteit Brussel; Brussels Belgium

3. Radioisotopes and Silicon Production Unit, Belgian Reactor 2 Expert Group; Belgian Nuclear Research Center (SCK•CEN); Mol Belgium

4. Department of Molecular and Cellular Interactions; Vlaams Instituut voor Biotechnologie; Brussels Belgium

5. Department of Cellular and Molecular Immunology; Vrije Universiteit Brussel; Brussel Belgium

6. Department of Nuclear Medicine; UZ Brussel; Brussels Belgium

Publisher

Wiley

Subject

Radiology Nuclear Medicine and imaging

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cmmi.491/fullpdf

Reference27 articles.

1. Intracellular signaling pathways of ErbB2/HER-2 and family members;Olayioye;Breast Cancer Res,2001

2. ERBB receptors and cancer: the complexity of targeted inhibitors;Hynes;Nat Rev Cancer,2005

3. Biology of HER2 and its importance in breast cancer;Yarden;Oncology,2001

4. HER2 breast cancer: review of biologic relevance and optimal use of diagnostic tools;Hicks;Am J Clin Pathol,2008

5. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer;Agus;J Clin Oncol,2005

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes;Cancer Treatment Reviews;2024-11

2. Immunologische Tracerentwicklung mit Nanobodies;Angewandte Nuklearmedizin;2024-03

3. Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies;Cancer Cell International;2024-02-10

4. NanoLAS: a comprehensive nanobody database with data integration, consolidation and application;Database;2024-01-01

5. NanoLAS: a Comprehensive Nanobody Database with Data Integration, Consolidation, and Application;2023-09-29